51
|
González-Regueiro JA, Higuera-de la Tijera MF, Moreno-Alcántar R, Torre A. Pathophysiology of hepatic encephalopathy and future treatment options. REVISTA DE GASTROENTEROLOGIA DE MEXICO (ENGLISH) 2019; 84:195-203. [PMID: 31014748 DOI: 10.1016/j.rgmx.2019.02.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 01/28/2019] [Accepted: 02/18/2019] [Indexed: 06/09/2023]
Abstract
Understanding of the pathophysiology of hepatic encephalopathy has conditioned new treatment options. Ammonia detoxification in hepatic encephalopathy is regulated by two enzymes: glutaminase or glutamine synthetase. The first produces ammonia and the second detoxifies the ammonia, which is why treatments are aimed at glutaminase inhibition or glutamine synthetase activation. At present, we know that both enzymes are found not only in the liver, but also in the muscle, intestine, kidney, and brain. Therefore, current treatments can be directed at each enzyme at different sites. Awareness of those potential treatment sites makes different options of approach possible in the patient with hepatic encephalopathy, and each approach should be personalized.
Collapse
Affiliation(s)
- J A González-Regueiro
- Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición «Salvador Zubirán», Ciudad de México, México
| | | | - R Moreno-Alcántar
- Departamento de Gastroenterología, Centro Médico Nacional Siglo XXI, Ciudad de México, México
| | - A Torre
- Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición «Salvador Zubirán», Ciudad de México, México; Unidad de Hepatología y Trasplante Hepático, Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición «Salvador Zubirán», Ciudad de México, México.
| |
Collapse
|
52
|
A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. J Clin Gastroenterol 2019; 53:226-230. [PMID: 29668561 DOI: 10.1097/mcg.0000000000001040] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND AND AIMS Hepatic encephalopathy (HE) is a reversible spectrum of neuropsychiatric abnormalities associated with liver dysfunction. Lactulose is a nonabsorbable disaccharide presently used to treat HE. Nitazoxanide (NTZ) has a broad-spectrum activity against urease-producing bacteria, so it decreases ammonia production and is therefore expected to reverse the symptoms of HE. A previous pilot study on HE patients given NTZ and lactulose had encouraging results with regard to amelioration of the clinical picture. Patients showed improvement in mental status and the drug was well-tolerated. Results such as these are encouraging larger studies. The aim of this study was to compare the safety and adequacy of NTZ plus lactulose versus lactulose and placebo in management of overt HE. METHODS In total, 120 cirrhotic patients suffering from overt HE were randomly designated to take either NTZ plus lactulose (n=60) or lactulose and placebo (n=60). The Clinical Hepatic Encephalopathy Staging Scale (CHESS) score was assessed for all patients on inclusion to the study and 1 week from the start of treatment. RESULTS Both groups evinced an improvement in CHESS score at 1 week, yet the improvement was significantly better in the NTZ group as the score decreased from 4.15±2.09 to 0.00±0.00 compared with 4.96±2.29 to 1.28±0.91 in patients receiving lactulose and placebo (P-value <0.001). CONCLUSIONS NTZ significantly decreases the CHESS score and improves mental status in the form of patient alertness, orientation, response to stimulation, and ability to talk. NTZ is safe and well-tolerated apart from infrequent epigastric pain.
Collapse
|
53
|
|
54
|
Lima LCD, Miranda AS, Ferreira RN, Rachid MA, Simões E Silva AC. Hepatic encephalopathy: Lessons from preclinical studies. World J Hepatol 2019; 11:173-185. [PMID: 30820267 PMCID: PMC6393717 DOI: 10.4254/wjh.v11.i2.173] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 11/19/2018] [Accepted: 01/28/2019] [Indexed: 02/06/2023] Open
Abstract
Hepatic encephalopathy (HE) is a major complication that is closely related to the progression of end-stage liver disease. Metabolic changes in advanced liver failure can promote cognition impairment, attention deficits and motor dysfunction that may result in coma and death. HE can be subdivided according to the type of hepatic injury, namely, type A, which results from acute liver failure, type B, which is associated with a portosystemic shunting without intrinsic liver disease, and type C, which is due to chronic liver disease. Several studies have investigated the pathogenesis of the disease, and most of the mechanisms have been explored using animal models. This article aimed to review the use of preclinical models to investigate HE. The most used animal species are rats and mice. Experimental models of type A HE include surgical procedures and the administration of hepatotoxic medications, whereas models of types B and C HE are generally surgically induced lesions in liver tissue, which evolve to hepatic cirrhosis. Preclinical models have allowed the comprehension of the pathways related to HE.
Collapse
Affiliation(s)
- Luiza Cioglia Dias Lima
- Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais 31270-901, Brasil
| | - Aline Silva Miranda
- Departamento de Morfologia, Instituto de Ciências Biológicas, UFMG, Belo Horizonte, Minas Gerais 30130-100, Brasil
| | - Rodrigo Novaes Ferreira
- Departamento de Morfologia, Instituto de Ciências Biológicas, UFMG, Belo Horizonte, Minas Gerais 30130-100, Brasil
| | - Milene Alvarenga Rachid
- Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais 31270-901, Brasil
| | - Ana Cristina Simões E Silva
- Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, UFMG, Belo Horizonte, Minas Gerais 30130-100, Brasil.
| |
Collapse
|
55
|
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2019; 51:190-205. [PMID: 30606696 DOI: 10.1016/j.dld.2018.11.035] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 11/27/2018] [Accepted: 11/28/2018] [Indexed: 12/11/2022]
Abstract
Hepatic encephalopathy (HE) is a common, worrisome and sometimes difficult to manage complication of end-stage liver disease. HE is often recurrent, requiring multiple hospital admissions. It can have serious implications in terms of a patient's ability to perform complex tasks (for example driving), their earning capacity, their social and family roles. This guideline reviews current knowledge on HE definition, pathophysiology, diagnosis and treatment, both by general principles and by way of a summary of available drugs and treatment strategies. The quality of the published, pertinent evidence is graded, and practical recommendations are made. Where possible, these are placed within the Italian health service context, with reference to local diagnosis and management experience.
Collapse
|
56
|
Marois C, Quirins M, Hermann B, Mouri S, Bouzbib C, Rudler M, Thabut D, Weiss N. [Metabolic encephalopathies]. Rev Med Interne 2019; 40:88-97. [PMID: 30638703 DOI: 10.1016/j.revmed.2018.11.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 11/12/2018] [Accepted: 11/15/2018] [Indexed: 12/16/2022]
Abstract
Metabolic encephalopathies (ME) are a common cause of admission to emergency rooms, to hospitalization wards or to intensive care units. They could account for 10 to 20% of causes of comatose states in ICU and could be associated to a poor outcome especially in older patients. Nevertheless, they are often reversible and are associated with a favorable outcome when diagnosed and rapidly treated. They correspond to an altered brain functioning secondary to the deficiency of a substance that is mandatory for the normal brain functioning or to the accumulation of a substance that can be either endogenous or exogenous. It preferably occurs in co-morbid patients, complicating its diagnosis and its management. Altered brain functioning, going from mild neuropsychological impairment to coma, movement disorders especially myoclonus and the absence of any obvious differential diagnosis are highly suggestive of the diagnosis. Whereas some biological samplings and brain MRI are essential to rule out differential diagnosis, some others, such as electroencephalogram, may be able to propose important clues in favor of the diagnosis. Once simple symptomatic measures are introduced, the treatment consists mainly in the correction of the cause. Specific treatment options are only seldom available for ME; this is the case for hepatic encephalopathy and some drug-induced encephalopathies. We will successively describe in this review the main pathophysiological mechanisms, the main causes, favoring circumstances of ME, the differential diagnosis to rule out and the etiological work-up for the diagnosis. Finally, a diagnostic and therapeutic strategy for the care of patients with ME will be proposed.
Collapse
Affiliation(s)
- C Marois
- Unité de réanimation neurologique, département de neurologie, Sorbonne université, groupement hospitalier Pitié-Salpêtrière Charles-Foix, Assistance publique des hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - M Quirins
- Service de neurologie adulte, hôpital Bicêtre, Assistance publique des hôpitaux de Paris (AP-HP), 94250 Le Kremlin-Bicêtre, France
| | - B Hermann
- Unité de réanimation neurologique, département de neurologie, Sorbonne université, groupement hospitalier Pitié-Salpêtrière Charles-Foix, Assistance publique des hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - S Mouri
- Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, unité de soins intensifs d'hépatologie, service d'hépato-gastroentérologie, Inserm, centre de recherche Saint-Antoine, Sorbonne université, groupement hospitalier Pitié-Salpêtrière Charles-Foix, Assistance publique des hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - C Bouzbib
- Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, unité de soins intensifs d'hépatologie, service d'hépato-gastroentérologie, Inserm, centre de recherche Saint-Antoine, Sorbonne université, groupement hospitalier Pitié-Salpêtrière Charles-Foix, Assistance publique des hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - M Rudler
- Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, unité de soins intensifs d'hépatologie, service d'hépato-gastroentérologie, Inserm, centre de recherche Saint-Antoine, Sorbonne université, groupement hospitalier Pitié-Salpêtrière Charles-Foix, Assistance publique des hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - D Thabut
- Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, unité de soins intensifs d'hépatologie, service d'hépato-gastroentérologie, Inserm, centre de recherche Saint-Antoine, Sorbonne université, groupement hospitalier Pitié-Salpêtrière Charles-Foix, Assistance publique des hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - N Weiss
- Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, unité de réanimation neurologique, département de neurologie, Inserm, centre de recherche Saint-Antoine, Sorbonne université, groupement hospitalier Pitié-Salpêtrière Charles-Foix, Assistance publique des hôpitaux de Paris (AP-HP), 47-83, boulevard de l'Hôpital, 75013 Paris, France.
| |
Collapse
|
57
|
|
58
|
Ning Q. Main Complications of AECHB and Severe Hepatitis B (Liver Failure). ACUTE EXACERBATION OF CHRONIC HEPATITIS B 2019. [PMCID: PMC7498917 DOI: 10.1007/978-94-024-1603-9_2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Qin Ning
- Department of Infectious Disease, Tongji Hospital, Wuhan, China
| |
Collapse
|
59
|
Ridola L, Nardelli S, Gioia S, Riggio O. How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy. J Clin Exp Hepatol 2019; 9:137-145. [PMID: 30765947 PMCID: PMC6363957 DOI: 10.1016/j.jceh.2018.02.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 02/20/2018] [Indexed: 12/12/2022] Open
Abstract
The design of clinical trials on Hepatic Encephalopathy (HE) is not an easy task, in fact there are several issues related to the performance of clinical trials in HE that have impeded progress in the field, mainly because most of the studies on HE therapy were performed before the era of rigorous Randomized Controlled Trials (RCTs). In this review we discuss the major problems affecting previously published trials on HE treatments aiming to provide evidences, suggestions and indications to prepare well designed RCTs in three different settings: (1) management of hospitalized patients with episodic HE; (2) secondary prophylaxis in patients following an episode of HE; and (3) management of minimal/covert HE.
Collapse
Affiliation(s)
- Lorenzo Ridola
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy
- Address for correspondence: Lorenzo Ridola, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica, 04110 Latina, Italy.
| | - Silvia Nardelli
- Department of Clinical Medicine, Sapienza University of Rome, Italy
| | - Stefania Gioia
- Department of Clinical Medicine, Sapienza University of Rome, Italy
| | - Oliviero Riggio
- Department of Clinical Medicine, Sapienza University of Rome, Italy
| |
Collapse
|
60
|
Fiati Kenston SS, Song X, Li Z, Zhao J. Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy. J Gastroenterol Hepatol 2019; 34:31-39. [PMID: 30070387 DOI: 10.1111/jgh.14408] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2018] [Revised: 07/02/2018] [Accepted: 07/18/2018] [Indexed: 12/14/2022]
Abstract
Hepatic encephalopathy is a neuropsychological syndrome due to biochemical disturbance of brain function in advanced liver disease patients. Diagnosis and treatment of the condition is very demanding and has negative toll on finances with increased healthcare utilization. The pathophysiology is not completely understood; however, there is evidence that ammonia plays an important role in the etiology. Conventional methods of solely relying on blood ammonia level to diagnose hepatic encephalopathy did not help much; likewise, the use of lactulose alone in treating hepatic encephalopathy has also been discouraged. This paper analyzed the current knowledge regarding the mechanism of how ammonia disrupts the normal brain function as well as the use of latest diagnosing tools including those under development to evaluate the neuropsychiatric state of patients and their quality of life. The efficacies of lactulose and rifaximin combination for short-term and long-term treatment in addition to nutritional interventions and other drugs undergoing clinical trials were also reviewed.
Collapse
Affiliation(s)
- Samuel Selorm Fiati Kenston
- Zhejiang Key Laboratory of Medicine and Pathophysiology, Ningbo University Medical School, Ningbo, Zhejiang Province, China.,Department of Medicine, Affiliated Hospital of Ningbo University Medical School, Ningbo, Zhejiang Province, China
| | - Xin Song
- Zhejiang Key Laboratory of Medicine and Pathophysiology, Ningbo University Medical School, Ningbo, Zhejiang Province, China
| | - Zhou Li
- Zhejiang Key Laboratory of Medicine and Pathophysiology, Ningbo University Medical School, Ningbo, Zhejiang Province, China
| | - Jinshun Zhao
- Zhejiang Key Laboratory of Medicine and Pathophysiology, Ningbo University Medical School, Ningbo, Zhejiang Province, China.,Department of Medicine, Affiliated Hospital of Ningbo University Medical School, Ningbo, Zhejiang Province, China
| |
Collapse
|
61
|
Affiliation(s)
- Chathur Acharya
- Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, USA
| | - Jasmohan S Bajaj
- Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, USA
| |
Collapse
|
62
|
Bajaj JS, Kakiyama G, Savidge T, Takei H, Kassam ZA, Fagan A, Gavis EA, Pandak WM, Nittono H, Hylemon PB, Boonma P, Haag A, Heuman DM, Fuchs M, John B, Sikaroodi M, Gillevet PM. Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. Hepatology 2018; 68:1549-1558. [PMID: 29665102 DOI: 10.1002/hep.30037] [Citation(s) in RCA: 96] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 04/02/2018] [Accepted: 04/06/2018] [Indexed: 12/11/2022]
Abstract
UNLABELLED Patients with cirrhosis are often exposed to antibiotics that can lead to resistance and fungal overgrowth. The role of fecal microbial transplant (FMT) in restoring gut microbial function is unclear in cirrhosis. In a Food and Drug Administration-monitored phase 1 clinical safety trial, patients with decompensated cirrhosis on standard therapies (lactulose and rifaximin) were randomized to standard-of-care (SOC, no antibiotics/FMT) or 5 days of broad-spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae. Microbial composition (diversity, family-level relative abundances), function (fecal bile acid [BA] deconjugation, 7α-dehydroxylation, short-chain fatty acids [SCFAs]), and correlations between Lachnospiraceae, Ruminococcaceae, and clinical variables were analyzed at baseline, postantibiotics, and 15 days post-FMT. FMT was well tolerated. Postantibiotics, there was a reduced microbial diversity and autochthonous taxa relative abundance. This was associated with an altered fecal SCFA and BA profile. Correlation linkage changes from beneficial at baseline to negative after antibiotics. All of these parameters became statistically similar post-FMT to baseline levels. No changes were seen in the SOC group. CONCLUSION In patients with advanced cirrhosis on lactulose and rifaximin, FMT restored antibiotic-associated disruption in microbial diversity and function. (Hepatology 2018; 00:000-000).
Collapse
Affiliation(s)
- Jasmohan S Bajaj
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | - Genta Kakiyama
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | - Tor Savidge
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX
| | - Hajime Takei
- Junshin Clinic Bile Acid Institute, Tokyo, Japan
| | | | - Andrew Fagan
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | - Edith A Gavis
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | - William M Pandak
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | | | - Phillip B Hylemon
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | - Prapaporn Boonma
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX
| | - Anthony Haag
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX
| | - Douglas M Heuman
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | - Michael Fuchs
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | - Binu John
- Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA
| | | | | |
Collapse
|
63
|
Amodio P. Hepatic encephalopathy: Diagnosis and management. Liver Int 2018; 38:966-975. [PMID: 29624860 DOI: 10.1111/liv.13752] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Accepted: 03/28/2018] [Indexed: 02/07/2023]
Abstract
Hepatic encephalopathy (HE) is a peculiar kind of brain dysfunction caused by liver insufficiency and/or portal-systemic shunting. It is related to gut-derived substances. It is a relevant cause of morbidity and hospitalisation for patients with cirrhosis. The prognosis of HE is important in terms of survival and re-hospitalisation. It is related to impaired quality of life, falls and poor driving; presents a relevant burden for caregivers and health services; and may negatively impact on patient's job and income. Proper diagnosis and classification are expected to improve HE management. Once diagnosed, the management and therapeutic options for HE are generally clear. The improvement of knowledge in recent years has also clarified which are the further aims of research in this field of medicine. Prophylaxis of overt HE should always be performed, and this is generally secondary prophylaxis. Primary prophylaxis should be done immediately after upper gastrointestinal bleeding. Great advances in the detection and treatment of mild forms of HE are expected to lead to further improvement in patient management.
Collapse
Affiliation(s)
- Piero Amodio
- Department of Medicine -DIMED- and CIRMANMEC, University of Padova, Padova, Italy
| |
Collapse
|
64
|
Kornerup LS, Gluud LL, Vilstrup H, Dam G. Update on the Therapeutic Management of Hepatic Encephalopathy. Curr Gastroenterol Rep 2018; 20:21. [PMID: 29644492 PMCID: PMC5895665 DOI: 10.1007/s11894-018-0627-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
Abstract
PURPOSE OF REVIEW Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments. RECENT FINDINGS Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.
Collapse
Affiliation(s)
- Linda Skibsted Kornerup
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, 44 Norrebrogade, 8000, Aarhus, Denmark.
| | - Lise Lotte Gluud
- Gastrounit, Medical Division, Copenhagen University Hospital, Kettegaard Allé 30, Hvidovre, 2650, Denmark
| | - Hendrik Vilstrup
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, 44 Norrebrogade, 8000, Aarhus, Denmark
| | - Gitte Dam
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, 44 Norrebrogade, 8000, Aarhus, Denmark
| |
Collapse
|
65
|
Carrier P, Loustaud-Ratti V. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Fundam Clin Pharmacol 2018; 32:206-208. [DOI: 10.1111/fcp.12353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Paul Carrier
- Hepatology and Gastroenterology Unit; Limoges Teaching Hospital; 2, avenue Martin Luther King 87042 Limoges France
- Faculté de Médecine et de Pharmacie de Limoges; INSERM; UMR-1248; 2, rue Docteur Marcland 87042 Limoges France
- FHU SUPORT (SUrvival oPtimization in ORgan Transplantation); 2, avenue Martin Luther King 87042 Limoges France
| | - Véronique Loustaud-Ratti
- Hepatology and Gastroenterology Unit; Limoges Teaching Hospital; 2, avenue Martin Luther King 87042 Limoges France
- Faculté de Médecine et de Pharmacie de Limoges; INSERM; UMR-1248; 2, rue Docteur Marcland 87042 Limoges France
- FHU SUPORT (SUrvival oPtimization in ORgan Transplantation); 2, avenue Martin Luther King 87042 Limoges France
| |
Collapse
|
66
|
Abstract
Hepatic encephalopathy (HE) is a common complication of liver dysfunction, including acute liver failure and liver cirrhosis. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma. It is a significant contributor of morbidity in patients with liver disease. HE is observed in acute liver failure, liver bypass procedures, for example, shunt surgry and transjugular intrahepatic portosystemic shunt, and cirrhosis. These are classified as Type A, B and C HE, respectively. HE can also be classified according to whether its presence is overt or covert. The pathogenesis is linked with ammonia and glutamine production, and treatment is based on mechanisms to reduce the formation and/or removal of these compounds. There is no specific diagnostic test for HE, and diagnosis is based on clinical suspicion, excluding other causes and use of clinical tests that may support its diagnosis. Many tests are used in trials and experimentally, but have not yet gained universal acceptance. This review focuses on the definitions, pathogenesis and treatment of HE. Consideration will be given to existing treatment, including avoidance of precipitating factors and novel therapies such as prebiotics, probiotics, antibiotics, laxatives, branched-chain amino acids, shunt embolization and the importance of considering liver transplant in appropriate cases.
Collapse
Affiliation(s)
| | - Mark Alexander Ellul
- Faculty of Health and Life Sciences, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
| | - Timothy JS Cross
- Department of Gastroenterology, Royal Liverpool University Hospital
| |
Collapse
|
67
|
Bing OHL. Hypothesis: role for ammonia neutralization in the prevention and reversal of heart failure. Am J Physiol Heart Circ Physiol 2018; 314:H1049-H1052. [PMID: 29547022 DOI: 10.1152/ajpheart.00003.2018] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Ammonia plays a central role in the life and death of all living organisms and has been studied for over 100 yr. Ammonia is necessary for growth and development, but it is toxic in excess, and, as a result, differing methods of ammonia neutralization have evolved. After physiological and pathological stress to the heart, tissue ammonia levels rise. Local ammonia neutralization may be inadequate, and excess ammonia may exert its toxic effects. Phenylbutyrate (PBA), which is Federal Drug Administration approved for the treatment of elevated blood ammonia in urea cycle disorders, provides an accessory pathway for ammonia excretion. Recently, PBA has also been found to prevent specific cardiomyopathies. The central theme presents the hypothesis that stress to the myocardium from a variety of environmental sources causes injury, cell death, necrosis, and ammonia production. Ammonia, if not neutralized, exerts downstream toxic effects. Here, data are presented showing that neutralization with PBA alone and PBA combined with angiotensin-converting enzyme inhibition prevent and reverse pathophysiology associated with specific cardiomyopathies. NEW & NOTEWORTHY Ammonia produced after myocardial injury is hypothesized to be an upstream stress contributing to the pathophysiology of heart failure, effects that may be attenuated by a documented ammonia-reducing treatment. Reversal of heart failure can be achieved using an angiotensin-converting enzyme inhibitor combined with an ammonia-reducing treatment.
Collapse
Affiliation(s)
- Oscar H L Bing
- Boston Veterans Affairs Medical Center , Boston, Massachusetts
| |
Collapse
|
68
|
The Pharmabiotic Approach to Treat Hyperammonemia. Nutrients 2018; 10:nu10020140. [PMID: 29382084 PMCID: PMC5852716 DOI: 10.3390/nu10020140] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 01/22/2018] [Accepted: 01/26/2018] [Indexed: 12/12/2022] Open
Abstract
Ammonia is constantly produced as a metabolic waste from amino acid catabolism in mammals. Ammonia, the toxic waste metabolite, is resolved in the liver where the urea cycle converts free ammonia to urea. Liver malfunctions cause hyperammonemia that leads to central nervous system (CNS) dysfunctions, such as brain edema, convulsions, and coma. The current treatments for hyperammonemia, such as antibiotics or lactulose, are designed to decrease the intestinal production of ammonia and/or its absorption into the body and are not effective, besides being often accompanied by side effects. In recent years, increasing evidence has shown that modifications of the gut microbiota could be used to treat hyperammonemia. Considering the role of the gut microbiota and the physiological characteristics of the intestine, the removal of ammonia from the intestine by modulating the gut microbiota would be an ideal approach to treat hyperammonemia. In this review, we discuss the significance of hyperammonemia and its related diseases and the efficacy of the current management methods for hyperammonemia to understand the mechanism of ammonia transport in the human body. The possibility to use the gut microbiota as pharmabiotics to treat hyperammonemia and its related diseases is also explored.
Collapse
|
69
|
Weiss N, Tripon S, Lodey M, Guiller E, Junot H, Monneret D, Mayaux J, Brisson H, Mallet M, Rudler M, Imbert-Bismut F, Thabut D. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Fundam Clin Pharmacol 2018; 32:209-215. [DOI: 10.1111/fcp.12340] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2017] [Revised: 10/21/2017] [Accepted: 12/01/2017] [Indexed: 01/04/2023]
Affiliation(s)
- Nicolas Weiss
- Brain-Liver Pitié-Salpêtrière Study Group (BLIPS); Hôpital de la Pitié-Salpêtrière; Assistance Publique-Hôpitaux de Paris; INSERM UMR_S 938, CDR Saint-Antoine & Institut de Cardiométabolisme et Nutrition (ICAN); 47-83 boulevard de l'Hôpital 75013 Paris France
- UPMC Univ Paris 06 & Unité de réanimation neurologique; Département de Neurologie; Pôle des maladies du système nerveux; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; Sorbonne Universités; 47-83 boulevard de l'Hôpital 75013 Paris France
- Institut de Neurosciences Translationnelles de Paris; Institut-Hospitalo-Universitaire-A-Institut du Cerveau et de la Moelle (IHU-A-ICM); 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Simona Tripon
- Brain-Liver Pitié-Salpêtrière Study Group (BLIPS); Hôpital de la Pitié-Salpêtrière; Assistance Publique-Hôpitaux de Paris; INSERM UMR_S 938, CDR Saint-Antoine & Institut de Cardiométabolisme et Nutrition (ICAN); 47-83 boulevard de l'Hôpital 75013 Paris France
- UPMC Univ Paris 06 & Soins Intensifs d'Hépatologie; Service d'Hépato-Gastroentérologie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Marion Lodey
- Service de pharmacie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Elsa Guiller
- Service de pharmacie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Helga Junot
- Service de pharmacie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Denis Monneret
- Brain-Liver Pitié-Salpêtrière Study Group (BLIPS); Hôpital de la Pitié-Salpêtrière; Assistance Publique-Hôpitaux de Paris; INSERM UMR_S 938, CDR Saint-Antoine & Institut de Cardiométabolisme et Nutrition (ICAN); 47-83 boulevard de l'Hôpital 75013 Paris France
- Service de biochimie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Julien Mayaux
- Unité de Réanimation et de Surveillance continue; Service de Pneumologie et Réanimation médicale; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Hélène Brisson
- Service de réanimation; Département d'anesthésie-réanimation; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Maxime Mallet
- Brain-Liver Pitié-Salpêtrière Study Group (BLIPS); Hôpital de la Pitié-Salpêtrière; Assistance Publique-Hôpitaux de Paris; INSERM UMR_S 938, CDR Saint-Antoine & Institut de Cardiométabolisme et Nutrition (ICAN); 47-83 boulevard de l'Hôpital 75013 Paris France
- UPMC Univ Paris 06 & Soins Intensifs d'Hépatologie; Service d'Hépato-Gastroentérologie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Marika Rudler
- Brain-Liver Pitié-Salpêtrière Study Group (BLIPS); Hôpital de la Pitié-Salpêtrière; Assistance Publique-Hôpitaux de Paris; INSERM UMR_S 938, CDR Saint-Antoine & Institut de Cardiométabolisme et Nutrition (ICAN); 47-83 boulevard de l'Hôpital 75013 Paris France
- UPMC Univ Paris 06 & Soins Intensifs d'Hépatologie; Service d'Hépato-Gastroentérologie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Françoise Imbert-Bismut
- Brain-Liver Pitié-Salpêtrière Study Group (BLIPS); Hôpital de la Pitié-Salpêtrière; Assistance Publique-Hôpitaux de Paris; INSERM UMR_S 938, CDR Saint-Antoine & Institut de Cardiométabolisme et Nutrition (ICAN); 47-83 boulevard de l'Hôpital 75013 Paris France
- Service de biochimie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | - Dominique Thabut
- Brain-Liver Pitié-Salpêtrière Study Group (BLIPS); Hôpital de la Pitié-Salpêtrière; Assistance Publique-Hôpitaux de Paris; INSERM UMR_S 938, CDR Saint-Antoine & Institut de Cardiométabolisme et Nutrition (ICAN); 47-83 boulevard de l'Hôpital 75013 Paris France
- UPMC Univ Paris 06 & Soins Intensifs d'Hépatologie; Service d'Hépato-Gastroentérologie; Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris; 47-83 boulevard de l'Hôpital 75013 Paris France
| | | |
Collapse
|
70
|
Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy: a critical current review. Hepatol Int 2017; 12:135-147. [PMID: 28770516 PMCID: PMC5830466 DOI: 10.1007/s12072-017-9812-3] [Citation(s) in RCA: 109] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2017] [Accepted: 07/06/2017] [Indexed: 12/12/2022]
Abstract
Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of cirrhosis and/or porto-systemic shunting. The clinical symptoms are widely variable, extending from subtle impairment in mental state to coma. The utility of categorizing the severity of HE accurately and efficiently serves not only to provide practical functional information about the current clinical status of the patient but also gives valuable prognostic information. In the past 20–30 years, there has been rapid progress in understanding the pathophysiological basis of HE; however, the lack of direct correlation between pathogenic factors and the severity of HE make it difficult to select appropriate therapy for HE patients. In this review, we will discuss the classification system and its limitations, the neuropsychometric assessments and their challenges, as well as the present knowledge on the pathophysiological mechanisms. Despite the many prevalent hypotheses around the pathogenesis of the disease, most treatments focus on targeting and lowering the accumulation of ammonia as well as inflammation. However, treatment of minimal HE remains a huge unmet need and a big concerted effort is needed to better define this condition to allow the development of new therapies. We review the currently available therapies and future approaches to treat HE as well as the scientific and clinical data that support their effectiveness.
Collapse
Affiliation(s)
- Anna Hadjihambi
- Division of Medicine, UCL Medical School, Royal Free Hospital, UCL Institute for Liver and Digestive Health, Rowland Hill Street, London, NW3 2PF, UK.,Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology and Pharmacology, University College London, London, WC1E 6BT, UK
| | - Natalia Arias
- Division of Medicine, UCL Medical School, Royal Free Hospital, UCL Institute for Liver and Digestive Health, Rowland Hill Street, London, NW3 2PF, UK.,INEUROPA (Instituto de Neurociencias del Principado de Asturias), Oviedo, Spain
| | - Mohammed Sheikh
- Division of Medicine, UCL Medical School, Royal Free Hospital, UCL Institute for Liver and Digestive Health, Rowland Hill Street, London, NW3 2PF, UK
| | - Rajiv Jalan
- Division of Medicine, UCL Medical School, Royal Free Hospital, UCL Institute for Liver and Digestive Health, Rowland Hill Street, London, NW3 2PF, UK.
| |
Collapse
|
71
|
Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver 2017; 10:509-19. [PMID: 27377741 PMCID: PMC4933409 DOI: 10.5009/gnl15419] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 08/31/2015] [Indexed: 12/18/2022] Open
Abstract
Hepatic encephalopathy is a spectrum of neurocognitive manifestations often seen in patients with liver injury or rarely in patients with portosystemic shunting without liver injury. It can be divided into minimal (covert) hepatic encephalopathy and overt hepatic encephalopathy, depending on the severity. Patients with hepatic encephalopathy have compromised clinical outcomes, decreased quality of life, and increased healthcare utilization, often resulting in a heavy financial and personal burden on caregivers. The diagnosis remains largely clinical, with the exclusion of possible other causes for the altered mental status. Current treatment strategies include nonabsorbable disaccharides and antibiotics. This review will focus on the diagnosis, management and clinical impact of hepatic encephalopathy.
Collapse
Affiliation(s)
| | - Vinay Sundaram
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Sammy Saab
- Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.,Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA
| |
Collapse
|
72
|
Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol 2017; 5:142-151. [PMID: 28660152 PMCID: PMC5472935 DOI: 10.14218/jcth.2016.00069] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 02/11/2017] [Accepted: 03/24/2017] [Indexed: 12/11/2022] Open
Abstract
Hepatic encephalopathy is a spectrum of reversible neuropsychiatric abnormalities, seen in patients with liver dysfunction and/or portosystemic shunting. One of the most debilitating complications of cirrhosis, encephalopathy affects 30-45% of cirrhotics. In addition to significantly affecting the lives of patients and their caregivers, it is also associated with increased morbidity and mortality as well as significant utilization of health care resources. In this paper, we provide an overview on the pathophysiology, diagnosis, management and newer therapies of hepatic encephalopathy.
Collapse
Affiliation(s)
- Saleh Elwir
- *Correspondence to: Saleh Elwir, Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, 3410 Worth Street, Suite 950, Dallas, TX 75246, USA. +1-214-820-8500, Fax: +1-214-820-0993, E-mail:
| | | |
Collapse
|
73
|
Abstract
Hepatic encephalopathy (HE) is a reversible syndrome of impaired brain function occurring in patients with advanced liver diseases. The precise pathophysiology of HE is still under discussion; the leading hypothesis focus on the role of neurotoxins, impaired neurotransmission due to metabolic changes in liver failure, changes in brain energy metabolism, systemic inflammatory response and alterations of the blood brain barrier. HE produces a wide spectrum of nonspecific neurological and psychiatric manifestations. Minimal HE is diagnosed by abnormal psychometric tests. Clinically overt HE includes personality changes, alterations in consciousness progressive disorientation in time and space, somnolence, stupor and, finally, coma. Except for clinical studies, no specific tests are required for diagnosis. HE is classified according to the underlying disease, the severity of manifestations, its time course and the existence of precipitating factors. Treatment of overt HE includes supportive therapies, treatment of precipitating factors, lactulose and/or rifaximin. Routine treatment for minimal HE is only recommended for selected patients.
Collapse
Affiliation(s)
- Peter Ferenci
- Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
74
|
Glutamine triggers long-lasting increase in striatal network activity in vitro. Exp Neurol 2017; 290:41-52. [DOI: 10.1016/j.expneurol.2017.01.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Revised: 12/05/2016] [Accepted: 01/04/2017] [Indexed: 01/04/2023]
|
75
|
de las Heras J, Aldámiz-Echevarría L, Martínez-Chantar ML, Delgado TC. An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease. Expert Opin Drug Metab Toxicol 2017; 13:439-448. [PMID: 27860485 PMCID: PMC5568887 DOI: 10.1080/17425255.2017.1262843] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
INTRODUCTION Ammonia-scavenging drugs, benzoate and phenylacetate (PA)/phenylbutyrate (PB), modulate hepatic nitrogen metabolism mainly by providing alternative pathways for nitrogen disposal. Areas covered: We review the major findings and potential novel applications of ammonia-scavenging drugs, focusing on urea cycle disorders and liver disease. Expert opinion: For over 40 years, ammonia-scavenging drugs have been used in the treatment of urea cycle disorders. Recently, the use of these compounds has been advocated in acute liver failure and cirrhosis for reducing hyperammonemic-induced hepatic encephalopathy. The efficacy and mechanisms underlying the antitumor effects of these ammonia-scavenging drugs in liver cancer are more controversial and are discussed in the review. Overall, as ammonia-scavenging drugs are usually safe and well tolerated among cancer patients, further studies should be instigated to explore the role of these drugs in liver cancer. Considering the relevance of glutamine metabolism to the progression and resolution of liver disease, we propose that ammonia-scavenging drugs might also be used to non-invasively probe liver glutamine metabolism in vivo. Finally, novel derivatives of classical ammonia-scavenging drugs with fewer and less severe adverse effects are currently being developed and used in clinical trials for the treatment of acute liver failure and cirrhosis.
Collapse
Affiliation(s)
- Javier de las Heras
- Division of Pediatric Metabolism, University Hospital of Cruces, Barakaldo, Bizkaia, Spain
- BioCruces Health Research Institute, Barakaldo, Bizkaia, Spain
- University of the Basque Country, Leioa, Bizkaia, Spain
| | - Luis Aldámiz-Echevarría
- Division of Pediatric Metabolism, University Hospital of Cruces, Barakaldo, Bizkaia, Spain
- BioCruces Health Research Institute, Barakaldo, Bizkaia, Spain
- University of the Basque Country, Leioa, Bizkaia, Spain
| | - María-Luz Martínez-Chantar
- University of the Basque Country, Leioa, Bizkaia, Spain
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Bizkaia, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain
| | - Teresa C. Delgado
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Bizkaia, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain
| |
Collapse
|
76
|
Abstract
This article reviews hepatic encephalopathy (HE) in companion animals. Clinical signs and categories of hepatic disease likely to cause HE are discussed. Ammonia has a key role in pathogenesis and current concepts in body ammonia metabolism are reviewed. Inflammation and manganese accumulation are also thought to be important in pathogenesis. Treatment of HE in acute and chronic cases is discussed along with the rationale for current treatment recommendations. Potential avenues for new treatments and human treatments, which may be transferable to companion animals, are reviewed.
Collapse
Affiliation(s)
- Adam G Gow
- Hospital for Small Animals, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, Edinburgh EH25 9RG, Scotland.
| |
Collapse
|
77
|
Patel VC, White H, Støy S, Bajaj JS, Shawcross DL. Clinical science workshop: targeting the gut-liver-brain axis. Metab Brain Dis 2016; 31:1327-1337. [PMID: 26446022 DOI: 10.1007/s11011-015-9743-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2015] [Accepted: 10/02/2015] [Indexed: 02/08/2023]
Abstract
A clinical science workshop was held at the ISHEN meeting in London on Friday 11th September 2014 with the aim of thrashing out how we might translate what we know about the central role of the gut-liver-brain axis into targets which we can use in the treatment of hepatic encephalopathy (HE). This review summarises the integral role that inter-organ ammonia metabolism plays in the pathogenesis of HE with specific discussion of the roles that the small and large intestine, liver, brain, kidney and muscle assume in ammonia and glutamine metabolism. Most recently, the salivary and gut microbiome have been shown to underpin the pathophysiological changes which culminate in HE and patients with advanced cirrhosis present with enteric dysbiosis with small bowel bacterial overgrowth and translocation of bacteria and their products across a leaky gut epithelial barrier. Resident macrophages within the liver are able to sense bacterial degradation products initiating a pro-inflammatory response within the hepatic parenchyma and release of cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-8 into the systemic circulation. The endotoxemia and systemic inflammatory response that are generated predispose both to the development of infection as well as the manifestation of covert and overt HE. Co-morbidities such as diabetes and insulin resistance, which commonly accompany cirrhosis, may promote slow gut transit, promote bacterial overgrowth and increase glutaminase activity and may need to be acknowledged in HE risk stratification assessments and therapeutic regimens. Therapies are discussed which target ammonia production, utilisation or excretion at an individual organ level, or which reduce systemic inflammation and endotoxemia which are known to exacerbate the cerebral effects of ammonia in HE. The ideal therapeutic strategy would be to use an agent that can reduce hyperammonemia and reduce systemic inflammation or perhaps to adopt a combination of therapies that can address both.
Collapse
Affiliation(s)
- Vishal C Patel
- Institute of Liver Studies, King's College London School of Medicine, King's College Hospital, King's College Hospital, Denmark Hill, London, SE5 9RS, UK
| | - Helen White
- Institute of Liver Studies, King's College London School of Medicine, King's College Hospital, King's College Hospital, Denmark Hill, London, SE5 9RS, UK
| | - Sidsel Støy
- Institute of Liver Studies, King's College London School of Medicine, King's College Hospital, King's College Hospital, Denmark Hill, London, SE5 9RS, UK
| | - Jasmohan S Bajaj
- McGuire VA Medical Center, Virginia Commonwealth University, Richmond, VA, USA
| | - Debbie L Shawcross
- Institute of Liver Studies, King's College London School of Medicine, King's College Hospital, King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
| |
Collapse
|
78
|
Kristiansen RG, Rose CF, Ytrebø LM. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy. Metab Brain Dis 2016; 31:1269-1273. [PMID: 27339764 DOI: 10.1007/s11011-016-9858-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 06/12/2016] [Indexed: 01/10/2023]
Abstract
Hepatic encephalopathy (HE) is a neuropsychiatric disorder caused by hepatic dysfunction. Numerous studies dictate that ammonia plays an important role in the pathogenesis of HE, and hyperammonemia can lead to alterations in amino acid homeostasis. Glutamine and glycine are both ammoniagenic amino acids that are increased in liver failure. Modulating the levels of glutamine and glycine has shown to reduce ammonia concentration in hyperammonemia. Ornithine Phenylacetate (OP) has consistently been shown to reduce arterial ammonia levels in liver failure by modulating glutamine levels. In addition to this, OP has also been found to modulate glycine concentration providing an additional ammonia removing effect. Data support that glycine also serves an important role in N-methyl D-aspartate (NMDA) receptor mediated neurotransmission in HE. This potential important role for glycine in the pathogenesis of HE merits further investigations.
Collapse
Affiliation(s)
- Rune Gangsøy Kristiansen
- Department of Anesthesiology, Anesthesia and Critical Care Research Group, University Hospital of North Norway and UiT-The Arctic University of Norway, Tromsø, Norway.
- Department of Anesthesiology, Ålesund Hospital, Helse Møre og Romsdal, 6010, Ålesund, Norway.
| | - Christopher F Rose
- Hepato-Neuro Laboratory, CRCHUM, Université de Montréal, Montréal, QC, Canada
| | - Lars Marius Ytrebø
- Department of Anesthesiology, Anesthesia and Critical Care Research Group, University Hospital of North Norway and UiT-The Arctic University of Norway, Tromsø, Norway
| |
Collapse
|
79
|
Amodio P, Montagnese S, Mullen K, Orr JG, Vilstrup H. Where are we going? Translational research in hepatic encephalopathy. Metab Brain Dis 2016; 31:1231-1237. [PMID: 26350697 DOI: 10.1007/s11011-015-9728-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Accepted: 09/02/2015] [Indexed: 01/27/2023]
Abstract
Translational medicine, rather than being a unidirectional clinical utilization of basic research discoveries, should be a bidirectional process of cross-fertilization between basic science, medical knowledge and clinical utilization. While steps and processes differ across these branches of research, clear language and proper definitions are prerequisites for effective interaction of researchers to facilitate knowledge development. With respect to Hepatic Encephalopathy, at first glance the areas which require development are around prevention, both to reduce the risk of relapse following an episode of overt HE and to reduce the risk of the first episode of HE. In addition, shortening the duration of episodes of overt HE may also be relevant. Comparisons of treatments and combinations of treatments, acting by different but potentially synergistic mechanisms, are reasonable targets for both basic and applied research.
Collapse
Affiliation(s)
- Piero Amodio
- Department of Medicine -DIMED, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy.
| | - Sara Montagnese
- Department of Medicine -DIMED, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy
| | - Kevin Mullen
- Case Western Reserve University School of Medicine, Cleveland, US
| | - James G Orr
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - Hendrik Vilstrup
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
| |
Collapse
|
80
|
Ventura-Cots M, Concepción M, Arranz JA, Simón-Talero M, Torrens M, Blanco-Grau A, Fuentes I, Suñé P, Alvarado-Tapias E, Gely C, Roman E, Mínguez B, Soriano G, Genescà J, Córdoba J. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol 2016; 9:823-835. [PMID: 27803737 PMCID: PMC5076769 DOI: 10.1177/1756283x16658252] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Ornithine phenylacetate (OP) has been proven effective in lowering ammonia plasma levels in animals, and to be well tolerated in cirrhotic patients. A trial to assess OP efficacy in lowering plasma ammonia levels versus placebo in cirrhotic patients after an upper gastrointestinal bleeding was performed. The primary outcome was a decrease in venous plasma ammonia at 24 hours. METHODS A total of 38 consecutive cirrhotic patients were enrolled within 24 hours of an upper gastrointestinal bleed. Patients were randomized (1:1) to receive OP (10 g/day) or glucosaline for 5 days. RESULTS The primary outcome was not achieved. A progressive decrease in ammonia was observed in both groups, being slightly greater in the OP group, with significant differences only at 120 hours. The subanalysis according to Child-Pugh score showed a statistically significant ammonia decrease in Child-Pugh C-treated patients at 36 hours, as well as in the time-normalized area under the curve (TN-AUC) 0-120 hours in the OP group [40.16 μmol/l (37.7-42.6); median (interquartile range) (IQR)] versus placebo group [65.5 μmol/l (54-126);p = 0.036]. A decrease in plasma glutamine levels was observed in the treated group compared with the placebo group, and was associated with the appearance of phenylacetylglutamine in urine. Adverse-event frequency was similar in both groups. No differences in hepatic encephalopathy incidence were observed. CONCLUSIONS OP failed to significantly decrease plasma ammonia at the given doses (10 g/day). Higher doses of OP might be required in Child-Pugh A and B patients. OP appeared well tolerated.
Collapse
Affiliation(s)
- Meritxell Ventura-Cots
- Liver Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Research and Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Mar Concepción
- Department of Medicine, Universitat Autònoma de Barcelona and Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Institut d’investigacions biomèdiques Sant Pau, Barcelona, Spain
| | - José Antonio Arranz
- Laboratory of Metabolic Diseases, Hospital Universitari Vall d’Hebron, Spain
| | - Macarena Simón-Talero
- Liver Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Research and Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Maria Torrens
- Liver Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Research, Barcelona, Spain
| | - Albert Blanco-Grau
- Laboratory of Metabolic Diseases, Hospital Universitari Vall d’Hebron, Spain
| | - Inma Fuentes
- Clinical Research Support Unit, Vall d’Hebron Institut of Research, UK
| | - Pilar Suñé
- Pharmacy Department, Hospital Universitari Vall d’Hebron, Spain
| | - Edilmar Alvarado-Tapias
- Department of Medicine, Universitat Autònoma de Barcelona and Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Institut d’Investigacions Biomèdiques Sant Pau, Barcelona, Spain
| | - Cristina Gely
- Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Institut d’Investigacions Biomèdiques Sant Pau, Barcelona, Spain
| | - Eva Roman
- Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Institut d’Investigacions Biomèdiques Sant Pau, Barcelona, Spain
| | - Beatriz Mínguez
- Liver Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Research and Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
| | - German Soriano
- Department of Medicine, Universitat Autònoma de Barcelona and Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Institut d’Investigacions Biomèdiques Sant Pau, Barcelona, Spain CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
| | | | - Juan Córdoba
- Liver Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Research and Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
81
|
Bajaj JS, Frederick RT, Bass NM, Ghabril M, Coyne K, Margolis MK, Santoro M, Coakley DF, Mokhtarani M, Jurek M, Scharschmidt BF. Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary. Metab Brain Dis 2016; 31:1081-93. [PMID: 27278222 DOI: 10.1007/s11011-016-9851-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2016] [Accepted: 06/01/2016] [Indexed: 12/22/2022]
Abstract
Clinical management and clinical trials of patients with overt hepatic encephalopathy (OHE) are compromised by lack of standardized and reproducible tools for its clinical diagnosis or for caregiver (CG) identification of OHE manifestations which merit medical evaluation. Using an iterative Delphi method, Steering Committee and international hepatologist panel, the West Haven (WH) scale was modified to develop and operationalize a clinician tool for OHE identification and grading (HE Grading Instrument, HEGI™). Major diagnostic criteria included disorientation to time, place, and person, asterixis, lethargy, and coma. Minimum HEGI requirements for OHE diagnosis included: (1) disorientation, or (2) presence of both lethargy and asterixis, or (3) coma. Inter- and intra-rater HEGI reproducibility were 97 % and 98 %, respectively. When applied to a phase II clinical trial population of 178 patients with 388 OHE episodes, HEGI demonstrated excellent concordance with investigator judgement. Additionally, a multi-stage study was conducted to develop a daily CG e-diary, based on OHE manifestations recognizable by CG including speech difficulties, unusual behavior, forgetfulness, confusion, disorientation and level of consciousness. The e-diary was designed for use on smart phone, laptop or desktop, utilized branching logic and skip patterns, incorporated automatic daily completion reminders and real time alerts to clinical sites to facilitate daily standardized CG input and was found to be user friendly and understandable. The HEGI and e-diary, which were developed using methodology accepted by regulatory authorities, are designed to facilitate the design and interpretation of clinical trials for OHE and improve outcomes for OHE patients in clinical practice.
Collapse
Affiliation(s)
- J S Bajaj
- Virginia Commonwealth University and McGuire VA Hospital, Richmond, VA, USA
| | - R T Frederick
- California Pacific Medical Center, San Francisco, CA, USA
| | - N M Bass
- University of California, San Francisco, CA, USA
| | - M Ghabril
- Indiana University, Indianapolis, IN, USA
| | | | - M K Margolis
- Patient-Centered Outcomes Research Institute, Washington, DC, USA
| | - M Santoro
- Horizon Pharma, 150 S Saunders Road, Lake Forest, IL, 60045, USA
| | - D F Coakley
- Horizon Pharma, 150 S Saunders Road, Lake Forest, IL, 60045, USA
| | - M Mokhtarani
- Horizon Pharma, 150 S Saunders Road, Lake Forest, IL, 60045, USA
| | - M Jurek
- Horizon Pharma, 150 S Saunders Road, Lake Forest, IL, 60045, USA
| | - B F Scharschmidt
- Horizon Pharma, 150 S Saunders Road, Lake Forest, IL, 60045, USA.
| |
Collapse
|
82
|
Zacharias HD, Zacharias AP, Oliveira Ferreira A, Morgan MY, Gluud LL. Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2016. [DOI: 10.1002/14651858.cd012334] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Harry D Zacharias
- Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; London UK NW3 2PF
| | - Antony P Zacharias
- Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; London UK NW3 2PF
| | - Alexandre Oliveira Ferreira
- Hospital Santa Maria; Department of Gastroenterology and Hepatology; Av Prof Egas Moniz Lisboa Portugal 1649
| | - Marsha Y Morgan
- Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; London UK NW3 2PF
| | - Lise Lotte Gluud
- Copenhagen University Hospital Hvidovre; Gastrounit, Medical Division; Kettegaards Alle Hvidovre Denmark 2650
| |
Collapse
|
83
|
L’encéphalopathie hépatique, du diagnostic au traitement en 2016. MEDECINE INTENSIVE REANIMATION 2016. [DOI: 10.1007/s13546-016-1223-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
84
|
Holecek M, Vodenicarovova M. Phenylbutyrate exerts adverse effects on liver regeneration and amino acid concentrations in partially hepatectomized rats. Int J Exp Pathol 2016; 97:278-84. [PMID: 27381898 DOI: 10.1111/iep.12190] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Accepted: 03/24/2016] [Indexed: 11/29/2022] Open
Abstract
Phenylbutyrate is recommended in urea cycle disorders and liver injury to enhance nitrogen disposal by the urine. However, hypothetically there may be adverse responses to the use of phenylbutyrate in the treatment of liver disease because of its role as a histone deacetylase inhibitor and its stimulatory effect on branched-chain alpha-keto acid dehydrogenase, the rate-limiting enzyme in the catabolism of branched-chain amino acids (BCAA; valine, leucine and isoleucine). We report the effects of phenylbutyrate on liver regeneration and amino acid levels in plasma of partially hepatectomized (PH) rats. Phenylbutyrate or saline was administered at 12-h intervals to PH or laparotomized rats. Phenylbutyrate delayed the onset of liver regeneration compared to the saline-treated controls, as indicated by lower hepatic DNA specific activities 18 and 24( ) h post-PH, decreased hepatic fractional protein synthesis rates 24 h post-PH and lowered the increases in liver weights and hepatic protein and DNA contents 48 h after PH. Hepatic DNA fragmentation (a hallmark of apoptosis) was higher in the phenylbutyrate-treated animals than in controls. Phenylbutyrate decreased the glutamine and BCAA concentrations and the ratio of the BCAA to aromatic amino acids (phenylalanine and tyrosine) in the blood plasma in both hepatectomized and laparotomized animals. In conclusion, the delayed onset of liver regeneration and the decrease in BCAA/AAA ratio in blood suggest that phenylbutyrate administration may be disastrous in subjects with acute hepatic injury and BCAA supplementation is needed when phenylbutyrate is used therapeutically.
Collapse
Affiliation(s)
- Milan Holecek
- Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
| | - Melita Vodenicarovova
- Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
| |
Collapse
|
85
|
Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therap Adv Gastroenterol 2016; 9:473-82. [PMID: 27366216 PMCID: PMC4913340 DOI: 10.1177/1756283x16644249] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome that occurs most often in a context of acute or chronic liver disease. Despite the seriousness of the pathology, only a few treatments have been developed for improving its management. Rifaximin-α is the first treatment that has been clinically developed for overt HE (OHE) episodes. Recent results of clinical studies demonstrated its significant improvement in the health-related quality of life. The objective of the current study was to estimate the long-term cost-effectiveness of rifaximin-α used in combination with lactulose compared with lactulose monotherapy in cirrhotic patients, who have experienced at least two prior OHE events. METHODS A Markov model was used to estimate rifaximin-α cost-effectiveness, evaluating it from the perspective of all contributors as recommended by French health technology assessment guidelines. Costs were based on current French treatment practices. The transition between health states was based on the reanalysis of the rifaximin-α pivotal clinical trials RFHE3001 and RFHE3002. The main outcome of the model was cost per quality adjusted life year (QALY). RESULTS The results indicate that rifaximin-α is a cost-effective treatment option with an incremental cost per QALY gained of €19,187 and €18,517 over two different time horizons (2 and 5 years). The robustness of the model was studied using probabilistic sensitivity analysis. CONCLUSION For the societal willingness to pay threshold of €27,000 per QALY gained, rifaximin-α in combination with lactulose is a cost-effective and affordable treatment for patients who have experienced at least two prior overt HE episodes.
Collapse
Affiliation(s)
| | - Soumaia Ben Hariz
- Network for Evaluation in Health Economics: REES France, Paris, France
| | - Elyonore Tsakeu
- Network for Evaluation in Health Economics: REES France, Paris, France
| | | | | |
Collapse
|
86
|
Abstract
OPINION STATEMENT Liver disease, both in its acute and chronic forms, can be associated with a wide spectrum of neurologic manifestations, both central and peripheral, ranging in severity from subclinical changes to neurocritical conditions. Neurologists are frequently consulted to participate in their management. In this review, we present an overview of management strategies for patients with hepatic disease whose clinical course is complicated by neurologic manifestations. Type A hepatic encephalopathy (HE), which occurs in acute liver failure, is a neurologic emergency, and multiple measures should be taken to prevent and treat cerebral edema. In Type C HE, which occurs in chronic liver disease, management should be aimed at correcting precipitant factors and hyperammonemia. There is an increasing spectrum of drug treatments available to minimize ammonia toxicity. Acquired hepatocerebral degeneration is a rare complication of the chronic form of HE, with typical clinical and brain MRI findings, whose most effective treatment is liver transplantation. Epilepsy is frequent and of multifactorial cause in patients with hepatic disease, and careful considerations should be made regarding choice of the appropriate anti-epileptic drugs. Several mechanisms increase the risk of stroke in hepatic disease, but many of the drugs used to treat and prevent stroke are contraindicated in severe hepatic failure. Hepatitis C infection increases the risk of ischemic stroke. Hemorrhagic stroke is more frequent in patients with liver disease of alcoholic etiology. Viral hepatitis is associated with a wide range of immune-mediated complications, mostly in the peripheral nervous system, which respond to different types of immunomodulatory treatment. Several drugs used to treat hepatic disease, such as the classical and the new direct-acting antivirals, may have neurologic complications which in some cases preclude its continued use.
Collapse
|
87
|
Vierling JM, Mokhtarani M, Brown RS, Mantry P, Rockey DC, Ghabril M, Rowell R, Jurek M, Coakley DF, Scharschmidt BF. Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2016; 14:903-906.e1. [PMID: 26707685 DOI: 10.1016/j.cgh.2015.11.018] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Revised: 11/12/2015] [Accepted: 11/25/2015] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS There is controversy over the use of measuring blood levels of ammonia (NH3) in the management of patients with overt hepatic encephalopathy (HE). METHODS We performed a retrospective analysis of data from a randomized, double-blind study of 178 patients with cirrhosis given glycerol phenylbutyrate (an NH3-lowering agent) or placebo for 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and NH3 levels were measured. The probabilities of having an HE episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of HE episodes in patients with baseline fasting NH3 levels ≤1.5-fold the upper limit of normal (ULN) versus patients with fasting NH3 levels >1.5-fold the ULN. RESULTS The risk and frequency of HE episodes and HE-related hospitalizations correlated with baseline (mean, 51 ± 6 μmol/L; ULN, 35 μmol/L) and on-study fasting levels of NH3, and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, NH3 exposure and the relative risk of HE episodes were decreased by glycerol phenylbutyrate. CONCLUSIONS In analysis of data from a phase 2 study of the effects of glycerol phenylbutyrate in patients with cirrhosis, we found that fasting levels of NH3 in blood can identify patients at risk for HE-related morbidity. Patients with HE might benefit from NH3-lowering therapy. ClinicalTrials.gov no: NCT 00999167.
Collapse
Affiliation(s)
| | | | | | - Parvez Mantry
- Liver Institute at Methodist Dallas Medical Center, Dallas, Texas
| | - Don C Rockey
- Medical University of South Carolina, Charleston, South Carolina
| | | | | | | | | | | |
Collapse
|
88
|
Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Dig Dis Sci 2016; 61:1728-34. [PMID: 26781427 DOI: 10.1007/s10620-016-4031-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 01/04/2016] [Indexed: 01/14/2023]
Abstract
BACKGROUND Overt hepatic encephalopathy (OHE) is a frequent complication of decompensated cirrhosis. AIMS A multicenter prospective observational study was performed to assess the most commonly recorded presenting manifestations of OHE and its associated health-care burden. METHODS Qualifying patients must have experienced ≥1 OHE episode within 30 days of enrollment (qualifying OHE) and were followed for recurrence (on-study OHE). RESULTS Two hundred and sixty-five patients were enrolled at 30 sites and followed for up to 9 months (mean 72 days). Seventy-two patients experienced 122 on-study episodes; with 72, 23, and 13 having ≥1, ≥2, or ≥3 on-study episodes with median days to occurrence of the 1st, 2nd, and 3rd episode of 34, 19, and 11, respectively. The most frequently recorded OHE manifestations included confusion (78 %), change in mental status (57 %), disorientation (48 %), lethargy (46 %), and asterixis (45 %). West Haven grade was used inconsistently and recorded for only 28 % of episodes. Most qualifying and on-study episodes occurred on rifaximin (60 and 82 %, respectively) and were associated with hospitalization (68 and 85 %, respectively). Twenty-three patients experienced ≥2 on-study episodes within 2 months of enrollment on average (median 45 days) and accounted for 60 % of on-study episodes. CONCLUSIONS In this prospective study, OHE's most commonly recorded presenting manifestations included confusion, altered mental status, disorientation, lethargy, and asterixis. As reflected by frequent recurrence and hospitalizations, OHE, particularly the approximately 10 % of "high-resource-utilizing" patients with frequent recurrence, continues to pose a major unmet medical need and health-care burden despite the use of rifaximin.
Collapse
|
89
|
Patwardhan VR, Jiang ZG, Risech-Neiman Y, Piatkowski G, Afdhal NH, Mukamal K, Curry MP, Tapper EB. Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis [corrected]. J Clin Gastroenterol 2016; 50:345-50. [PMID: 26565968 DOI: 10.1097/mcg.0000000000000443] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND As ammonia metabolism is a complex multiorgan process, we sought to determine whether serum ammonia concentrations were associated with transplant-free survival in patients with acutely decompensated cirrhosis and acute-on-chronic liver failure (ACLF). METHODS We studied 494 consecutive patients hospitalized with cirrhosis between April 2007 and September 2012 with venous ammonia measured on hospital admission. The primary outcome was transplant-free survival. RESULTS Overall, rates of death or transplant within 30 and 90 days were 23.1% (n=114) and 37.7% (n=186), respectively. Forty-six patients (9.2%) underwent liver transplantation within 90 days. In a multivariate Cox proportional hazards model, ammonia concentration was independently associated with death or transplantation within 30 and 90 days after adjusting for model for end-stage liver disease, sodium, white blood cells, and number of ACLF organ failures; every doubling of ammonia was associated with respective hazard ratios of 1.22 (95% confidence interval, 1.03-1.38) and 1.21 (95% confidence interval, 1.04-1.44) for 90- and 30-day transplant or mortality. Notably, after adjusting for ammonia, organ failures were not predictive of outcomes. In a Kaplan-Meier analysis, patients with admission ammonia concentrations >60 μmol/L had significantly lower 90-day transplant-free survival (P=0.0004). Patients with admission ammonia concentrations >60 μmol/L had higher 90- and 30-day risk of death or transplantation (45.2% vs. 31.2%, P=0.001; and 31.6% vs. 15.7%, P<0.0001, respectively). CONCLUSION For patients with acutely decompensated cirrhosis, an elevated serum ammonia concentration on admission is associated with reduced 90-day transplant-free survival after adjusting for established predictors.
Collapse
Affiliation(s)
- Vilas R Patwardhan
- *Division of Gastroenterology†Department of Medicine‡Decision Support, Beth Israel Deaconess Medical Center, Boston, MA
| | | | | | | | | | | | | | | |
Collapse
|
90
|
Abstract
In vitro studies have suggested that 4-phenylbutyrate (PBA) may rescue missense mutated proteins that underlie some forms of progressive familial intrahepatic cholestasis. Encouraging preliminary responses to 4-PBA have been reported in liver disease secondary to mutations in ABCB11 and ATP8B1. A 4-year-old boy with Byler disease was treated with 4-PBA in the forms of sodium PBA (5 months) and then glycerol PBA (7 months) as part of expanded access single patient protocols. During this therapy serum total bilirubin fell and his general well-being was reported to be improved, although total serum bile acids were not reduced. Discontinuation of rifampin therapy, which had been used to treat pruritus, resulted in reversible severe acute liver injury that was potentially the result of phenylacetate toxicity. Interactions between 4-PBA and cytochrome P450 enzymes should be considered in the use of this agent with special attention to potential phenylacetate toxicity.
Collapse
|
91
|
NeSmith M, Ahn J, Flamm SL. Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy. Gastroenterol Hepatol (N Y) 2016; 12:91-100. [PMID: 27182210 PMCID: PMC4865778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Hepatic encephalopathy (HE) is a major complication of liver disease that leads to significant morbidity and mortality. Caring for hospitalized patients with HE is becoming more complex, and the economic burden of HE continues to rise. Defining and diagnosing HE, particularly covert HE (CHE), remain challenging. In this article, we review new tools and those currently under development for the diagnosis of CHE and the latest advances in the acute and long-term management of overt HE (OHE) and CHE. In particular, we review the latest data on the use of lactulose and rifaximin for treatment of OHE and summarize the data on adjunctive agents such as sodium benzoate and probiotics.
Collapse
Affiliation(s)
- Meghan NeSmith
- Dr NeSmith is a gastroenterology fellow and Dr Ahn is an associate professor of medicine and director of clinical hepatology at Oregon Health & Science University in Portland, Oregon. Dr Flamm is a professor of medicine and chief of the liver transplantation program at Northwestern University Feinberg School of Medicine in Chicago, Illinois
| | - Joseph Ahn
- Dr NeSmith is a gastroenterology fellow and Dr Ahn is an associate professor of medicine and director of clinical hepatology at Oregon Health & Science University in Portland, Oregon. Dr Flamm is a professor of medicine and chief of the liver transplantation program at Northwestern University Feinberg School of Medicine in Chicago, Illinois
| | - Steven L Flamm
- Dr NeSmith is a gastroenterology fellow and Dr Ahn is an associate professor of medicine and director of clinical hepatology at Oregon Health & Science University in Portland, Oregon. Dr Flamm is a professor of medicine and chief of the liver transplantation program at Northwestern University Feinberg School of Medicine in Chicago, Illinois
| |
Collapse
|
92
|
Ferral H, Gomez-Reyes E, Fimmel CJ. Post-Transjugular Intrahepatic Portosystemic Shunt Follow-Up and Management in the VIATORR Era. Tech Vasc Interv Radiol 2016; 19:82-8. [PMID: 26997092 DOI: 10.1053/j.tvir.2016.01.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The transjugular intrahepatic portosystemic shunt (TIPS) is a non-selective portosystemic shunt created using endovascular techniques. The first TIPS was performed in Germany in 1988. The VIATORR self-expandable PTFE covered stent-graft (WL Gore, Flagstaff AZ) was approved by the FDA for a TIPS application in December of 2004. This stent-graft offers excellent shunt patency rates and it is possible that it has a beneficial effect on patient survival. Patient surveillance and post-procedural management have changed after the introduction of this stent-graft. This article presents the current management strategies that are followed at our Institution for patients who have undergone a TIPS procedure with a VIATORR stent graft including imaging follow-up, management of encephalopathy, medical management and nutritional aspects.
Collapse
Affiliation(s)
- Hector Ferral
- The Department of Radiology, Section of Interventional Radiology, NorthShore University HealthSystem, Evanston, IL.
| | - Elisa Gomez-Reyes
- Departamento de Gastroenterologia, Instituto Nacional de la Nutricion Salvador Zubiran, Tlalpan, Mexico City, Mexico
| | - Claus J Fimmel
- University of Chicago Pritzker School of Medicine, Section Chief of Hepatology, Division of Gastroenterology, NorthShore University HealthSystem, Evanston, IL
| |
Collapse
|
93
|
Variation in Liver Biochemistries in Patients with Decompensated Cirrhosis: Implications for Assessing Drug-Induced Liver Injury in Clinical Trials. Pharmaceut Med 2016. [DOI: 10.1007/s40290-015-0134-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
94
|
Silver SA, Cardinal H, Colwell K, Burger D, Dickhout JG. Acute kidney injury: preclinical innovations, challenges, and opportunities for translation. Can J Kidney Health Dis 2015; 2:30. [PMID: 26331054 PMCID: PMC4556308 DOI: 10.1186/s40697-015-0062-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Accepted: 07/02/2015] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Acute kidney injury (AKI) is a clinically important condition that has attracted a great deal of interest from the biomedical research community. However, acute kidney injury AKI research findings have yet to be translated into significant changes in clinical practice. OBJECTIVE This article reviews many of the preclinical innovations in acute kidney injury AKI treatment, and explores challenges and opportunities to translate these finding into clinical practice. SOURCES OF INFORMATION MEDLINE, ISI Web of Science. FINDINGS This paper details areas in biomedical research where translation of pre-clinical findings into clinical trials is ongoing, or nearing a point where trial design is warranted. Further, the paper examines ways that best practice in the management of AKI can reach a broader proportion of the patient population experiencing this condition. LIMITATIONS This review highlights pertinent literature from the perspective of the research interests of the authors for new translational work in AKI. As such, it does not represent a systematic review of all of the AKI literature. IMPLICATIONS Translation of findings from biomedical research into AKI therapy presents several challenges. These may be partly overcome by targeting populations for interventional trials where the likelihood of AKI is very high, and readily predictable. Further, specific clinics to follow-up with patients after AKI events hold promise to provide best practice in care, and to translate therapies into treatment for the broadest possible patient populations.
Collapse
Affiliation(s)
- Samuel A. Silver
- />Division of Nephrology, St. Michael’s Hospital, University of Toronto, Toronto, Canada
| | - Héloise Cardinal
- />Division of Nephrology, Centre Hospitalier de l’Université de Montréal and CHUM research center, Montreal, Quebec Canada
| | - Katelyn Colwell
- />Department of Medicine, Division of Nephrology, McMaster University and St. Joseph’s Healthcare Hamilton, Hamilton, Ontario Canada
| | - Dylan Burger
- />Kidney Research Centre, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario Canada
| | - Jeffrey G. Dickhout
- />Department of Medicine, Division of Nephrology, McMaster University and St. Joseph’s Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6 Canada
| |
Collapse
|
95
|
Abstract
Hepatic encephalopathy (HE) is defined by an altered mental status in the setting of portosystemic shunting, with or without cirrhosis. The basis of HE is probably multi-factorial, but increased ammonia delivery to the brain is thought to play a pivotal role. Medical therapies have typically focused on reducing blood ammonia concentrations. These measures are moderately effective, but further improvements will require identification of new therapeutic targets. Two medications, lactulose and rifaximin, are currently approved for the treatment of HE in the USA - new compounds are available off-label, and are in clinical trials. The presence of HE is associated with a higher risk of death in cirrhotic patients. Liver transplantation typically cures HE, but HE does not increase the MELD score, and therefore does not contribute to the likelihood of liver transplantation.
Collapse
Affiliation(s)
- Norman L Sussman
- Baylor College of Medicine and Baylor-St. Luke's Medical Center, Division of Abdominal Transplantation, 6620 Main Street #1425, Houston, TX 77030, USA.
| |
Collapse
|
96
|
Abstract
Normal regulation of total body and circulating ammonia requires a delicate interplay in ammonia formation and breakdown between several organ systems. In the setting of cirrhosis and portal hypertension, the decreased hepatic clearance of ammonia leads to significant dependence on skeletal muscle for ammonia detoxification; however, cirrhosis is also associated with muscle depletion and decreased functional muscle mass. Thus, patients with diminished muscle mass and sarcopenia may have a decreased ability to compensate for hepatic insufficiency and a higher likelihood of developing physiologically significant hyperammonemia and hepatic encephalopathy.
Collapse
Affiliation(s)
- Catherine Lucero
- Division of Digestive and Liver Diseases, Department of Medicine, Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH 14-105, New York, NY 10032, USA
| | - Elizabeth C Verna
- Division of Digestive and Liver Diseases, Department of Medicine, Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH 14-105, New York, NY 10032, USA.
| |
Collapse
|
97
|
Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev 2015; 90:55-68. [PMID: 25895618 DOI: 10.1016/j.addr.2015.04.009] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Revised: 03/30/2015] [Accepted: 04/13/2015] [Indexed: 02/07/2023]
Abstract
Ammonia is a neurotoxic agent that is primarily generated in the intestine and detoxified in the liver. Toxic increases in systemic ammonia levels predominantly result from an inherited or acquired impairment in hepatic detoxification and lead to potentially life-threatening neuropsychiatric symptoms. Inborn deficiencies in ammonia detoxification mainly affect the urea cycle, an endogenous metabolic removal system in the liver. Hepatic encephalopathy, on the other hand, is a hyperammonemia-related complication secondary to acquired liver function impairment. A range of therapeutic options is available to target either ammonia generation and absorption or ammonia removal. Therapies for hepatic encephalopathy decrease intestinal ammonia production and uptake. Treatments for urea cycle disorders eliminate ammoniagenic amino acids through metabolic transformation, preventing ammonia generation. Therapeutic approaches removing ammonia activate the urea cycle or the second essential endogenous ammonia detoxification system, glutamine synthesis. Recent advances in treating hyperammonemia include using synergistic combination treatments, broadening the indication of orphan drugs, and developing novel approaches to regenerate functional liver tissue. This manuscript reviews the various pharmacological treatments of hyperammonemia and focuses on biopharmaceutical and drug delivery issues.
Collapse
|
98
|
Abstract
Hepatic encephalopathy (HE) is a common complication of cirrhosis, leading to frequent hospitalizations. Because ammonia is thought to play an important role in the pathogenesis of HE, therapies specifically aimed at reducing ammonia levels have been developed for conditions causing hyperammonemia, including HE. Ammonia scavengers have been used in HE patients, leading to improvements in symptoms. Bowel cleansing with polyethylene glycol has also been studied recently, resulting in more rapid improvement in acute HE compared with lactulose. Extracorporeal devices have been used in cases of refractory HE but currently are used primarily in research settings and not approved for clinical management for HE.
Collapse
Affiliation(s)
- Robert S Rahimi
- Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, 3410 Worth Street, Suite 860, Dallas, TX 75246, USA.
| | - Don C Rockey
- Department of Internal Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Room 803 CSB, Charleston, SC 29425, USA
| |
Collapse
|
99
|
Abstract
Minimal hepatic encephalopathy (mHE) is common among patients with cirrhotic liver disease and causes significant morbidity and mortality. It may present as cognitive impairment, behavioural changes and, less frequently, with neurological symptoms which make diagnosis of the disease challenging. A history of falls and accidents may also be suggestive of mHE. Diagnosis primarily relies on at least two positive psychometric tests of which the psychometric hepatic encephalopathy score (PHES) is essential. Alternatively, PHES and an electroencephalogram may be used to establish a diagnosis. Biochemical markers of encephalopathy currently have no role in the diagnosis of mHE. Treatment is not always advocated for a diagnosis of mHE but is dependent on the degree of impairment caused by the symptoms. After treatment of other metabolic abnormalities and co-morbidities associated with cirrhosis, more specific treatment for mHE largely relies on therapies used to lower ammonia levels. Laxatives and rifaximin are commonly used in treatment and work through decreasing ammonia absorption from the gut. Other therapies, such as BCAA, LOLA, L-carnitine and phenylbutyrate, modify responses to ammonia as well as enhancing metabolism and excretion. mHE resulting from spontaneous portosystemic shunts or transhepatic intraportal systemic shunts may require ablation or reduction of the shunt. Early detection and appropriate treatment of mHE is important to prevent significant cognitive impairments and progression to overt HE.
Collapse
Affiliation(s)
- Shamindra Direkze
- Royal Free Hospital NHS Foundation Trust, University College London, London, UK
| | | |
Collapse
|
100
|
Affiliation(s)
- Anna Hadjihambi
- Institute for Liver and Digestive Health, Liver Failure Group, University College London Medical School Royal Free CampusLondonUK
| | - Rajiv Jalan
- Institute for Liver and Digestive Health, Liver Failure Group, University College London Medical School Royal Free CampusLondonUK
| |
Collapse
|